Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

Ekaterina Chigrinova(Institute of Oncology Research), Andrea Rinaldi(Institute of Oncology Research), Ivo Kwee(SIB Swiss Institute of Bioinformatics), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paola M. V. Rancoita(Dalle Molle Institute for Artificial Intelligence Research), Jonathan C. Strefford(University of Southampton), David Oscier(Royal Bournemouth Hospital), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Theodora Papadaki(G. Papanikolaou General Hospital), Françoise Berger(Université Claude Bernard Lyon 1), Ken H. Young(The University of Texas MD Anderson Cancer Center), Fiona Murray(Uppsala University), Richard Rosenquist(Uppsala University), Timothy C. Greiner(University of Nebraska Medical Center), Wing C. Chan(University of Nebraska Medical Center), Ester Orlandi(University of Pavia), Marco Lucioni(University of Pavia), Roberto Marasca(University of Modena and Reggio Emilia), Giorgio Inghirami(University of Turin), Marco Ladetto(Azienda Ospedaliero Universitaria San Giovanni Battista), Francesco Forconi(University of Siena), Sergio Cogliatti(University of St.Gallen), Hana Votavová(Institute of Haematology and Blood Transfusion), Steven H. Swerdlow(University of Pittsburgh), Stephan Stilgenbauer(Universität Ulm), Miguel Á. Piris(Marqués de Valdecilla University Hospital), András Matolcsy(Semmelweis University), Dominic V. Spagnolo(Pathwest Laboratory Medicine), Eugene Nikitin, Alberto Zamò(University of Verona), Valter Gattei(Centro di Riferimento Oncologico), Govind Bhagat(NewYork–Presbyterian Hospital), German Ott(Robert Bosch Hospital), Emanuele Zucca(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Francesco Bertoni(Institute of Oncology Research)
Blood
September 5, 2013
Cited by 249Open Access
Full Text

Abstract

Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL). Although RS, usually represented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated with a very poor outcome, especially when clonally related to the preexisting CLL, the mechanisms leading to RS have not been clarified. To better understand the pathogenesis of RS, we analyzed a series of cases including 59 RS, 28 CLL phase of RS, 315 CLL, and 127 de novo DLBCL. RS demonstrated a genomic complexity intermediate between CLL and DLBCL. Cell-cycle deregulation via inactivation of TP53 and of CDKN2A was a main mechanism in the histologic transformation from CLL phase, being present in approximately one half of the cases, and affected the outcome of the RS patients. A second major subgroup was characterized by the presence of trisomy 12 and comprised one third of the cases. Although RS shared some of the lesions seen in de novo DLBCL, its genomic profile was clearly separate. The CLL phase preceding RS had not a generalized increase in genomic complexity compared with untransformed CLL, but it presented clear differences in the frequency of specific genetic lesions.


Related Papers

No related papers found

Powered by citation graph analysis